Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of CytomX Therapeutics Inc (NASDAQ: CTMX) was $0.87 for the day, up 3.71% from the previous closing price of $0.84. In other words, the price has increased by $3.71 from its previous closing price. On the day, 1.11 million shares were traded. CTMX stock price reached its highest trading level at $0.888 during the session, while it also had its lowest trading level at $0.84.
Ratios:
Our analysis of CTMX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 20 ’24 when Landau Jeffrey B sold 4,181 shares for $1.23 per share. The transaction valued at 5,139 led to the insider holds 119,056 shares of the business.
BELVIN MARCIA sold 4,181 shares of CTMX for $5,139 on Aug 20 ’24. The SVP, Chief Scientific Officer now owns 175,648 shares after completing the transaction at $1.23 per share. On Aug 20 ’24, another insider, ROWLAND LLOYD A, who serves as the General Counsel of the company, sold 4,181 shares for $1.23 each. As a result, the insider received 5,139 and left with 130,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 68179152 and an Enterprise Value of -38811864. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.54. Its current Enterprise Value per Revenue stands at -0.307 whereas that against EBITDA is -4.539.
Stock Price History:
The Beta on a monthly basis for CTMX is 1.01, which has changed by -0.45098037 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -15.69%, while the 200-Day Moving Average is calculated to be -37.87%.
Shares Statistics:
CTMX traded an average of 1.31M shares per day over the past three months and 1283370 shares per day over the past ten days. A total of 78.23M shares are outstanding, with a floating share count of 76.94M. Insiders hold about 1.69% of the company’s shares, while institutions hold 63.87% stake in the company. Shares short for CTMX as of 1735603200 were 4798768 with a Short Ratio of 3.67, compared to 1732838400 on 4388410. Therefore, it implies a Short% of Shares Outstanding of 4798768 and a Short% of Float of 6.17.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate the current performance of CytomX Therapeutics Inc (CTMX) in the stock market.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.02 and low estimates of -$0.19.
Analysts are recommending an EPS of between $0.14 and -$0.04 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is -$0.42, with 5.0 analysts recommending between -$0.1 and -$0.95.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $33M to a low estimate of -$15.3M. As of the current estimate, CytomX Therapeutics Inc’s year-ago sales were $26.61MFor the next quarter, 6 analysts are estimating revenue of $18.5M. There is a high estimate of $33M for the next quarter, whereas the lowest estimate is $10M.
A total of 6 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $133.01M, while the lowest revenue estimate was $84.7M, resulting in an average revenue estimate of $115.72M. In the same quarter a year ago, actual revenue was $101.21MBased on 6 analysts’ estimates, the company’s revenue will be $80.57M in the next fiscal year. The high estimate is $132M and the low estimate is $31M.
